MarginsXMarginsX
Home › Markets › Health Care › DCOY

Decoy Therapeutics Inc. (DCOY)

DCOY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9010
-7.61% on the day
Market cap
$2.1M
Nano cap
Revenue · 2022
$0
-100.0% on 2021
Net income · 2022
-$31.6M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1615219/000161521923000030/0001615219-23-000030-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerDCOY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001615219
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2022

LineValue
Revenue$0
Net income-$31.6M
Operating income-$31.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$12.1M
Total assets$14.7M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
10.6 months
$8.2M cash at September 30, 2026
Share count, 1 year
+388.3%
2025-11-12 to 2026-11-11 · +87112.5% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$20K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$8.2M cash; operating cash flow -$2.3M a quarter.Report 2026-09-30
Shares outstanding2,385,282 (2026-11-11); 5,862,178 a year earlier; 3,938,433 three years earlier. 1y figure adjusted for splits (1-for-12 overall); 3y figure adjusted for splits (1-for-1440 overall).Cover page 2026-11-11
Reverse splits, 3 years3; latest 1-for-12 on 2026-03-09Source 2026-03-09
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-13
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-01-02
AuditorErnst & Young LLP, Houston, Texas, United StatesPCAOB Form AP 2026-04-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20K, sold $17 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$307K-$3.0M-$2.6M$8.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$228K-$2.4M-$2.7M$8.3MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$2.2M-$2.9M$7.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$9.0M-$1.1M$10.7M$0Needs four quarters10-K 2026-03-31
Q3 2025
2025-09-30
$0-$873K-$1.6M$4.8M$0Needs four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
$0-$958K-$862K$795K$0Needs four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$1.7M-$1.2M$1.8M$112KNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$1.5M-$743K$2.4M$222KNeeds four quarters10-K 2026-03-31

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-13
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-09-23
Latest proxyDEF 14A2026-08-04

Source: SEC EDGAR submissions feed, 746 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.7%
1 month-21.4%
3 months-72.4%
Year to date-87.5%
1 year-93.3%
From 52-week high-93.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SBFMSunshine Biopharma Inc.$2.60-3.70%$2.1M
CMNDClearmind Medicine Inc. Common Shares$4.18-7.67%$2.1M
JUNSJupiter Neurosciences Inc.$1.70-8.11%$2.2M
PPCBPropanc Biopharma Inc.$1.89-2.62%$2.0M
ONCOOnconetix Inc.$2.91-9.35%$1.9M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
XRTXXORTX Therapeutics Inc. Common Shares$1.04-5.45%$1.9M
GNPXGenprex Inc.$1.90-8.65%$2.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier